TaiMed Biologics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jimmy Chang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.2% |
| Management average tenure | no data |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook
Apr 20
TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%
Mar 16TaiMed Biologics'(GTSM:4147) Share Price Is Down 67% Over The Past Five Years.
Feb 09Loss-Making TaiMed Biologics Inc. (GTSM:4147) Set To Breakeven
Jan 05
TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?
Dec 01CEO
Jimmy Chang
2.9yrs
Tenure
Mr. Chin-Ming Chang, also known as "Jimmy", Ph D., serves as Independent director of Genovate Biotechnology Co., Ltd. since May 29, 2023.He has been President and Chief Executive Officer of TaiMed Biologi...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 8yrs | no data | no data | |
| Director | 6.7yrs | no data | no data | |
| Director | 11.9yrs | no data | 0.12% NT$ 26.9m | |
| Chairman & Spokesperson | 27.9yrs | no data | no data | |
| Independent Director | 4.9yrs | no data | no data | |
| Director | 4.3yrs | no data | 0.0015% NT$ 318.2k | |
| Director | 3yrs | no data | no data | |
| Independent Director | 3yrs | no data | no data | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data |
4.6yrs
Average Tenure
65.5yo
Average Age
Experienced Board: 4147's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 03:38 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TaiMed Biologics Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Chu Wang | Citigroup Inc |
| null null | Credit Suisse |